Header_Navigation
p_stu p_wei p_ser p_org p_for p_war

Prof. Dr. Zimmermann

Last modified: 04/05/2012 01:53 PM Print page
Molekulare Pharmakologie und Biochemie

Zur Person

zimmermann.jpg

Prof. Dr. Katharina Zimmermann geb. Schindowski

Professorin für die Lehrgebiete Molekulare Pharmakologie und Biochemie
Fachgebiet Pharmakologie, Biochemie, Immunologie und Physiologie

Kontaktdaten

  • Sprechzeiten Di 11:15 bis 12:15 und nach Vereinbarung
  • Telefon +49 (0)7351 - 582 498
  • Telefax +49 (0)7351 - 582 469
  • Büro Gebäude Pharmazeut. Biotechnologie P3.08

  • Mail an Frau Prof. Zimmermann

Lehrveranstaltungen

  • Biochemie des Stoffwechsels (Vorlesung)
  • Chemie der Biomoleküle (Praktikum)
  • Pharmakologie und Toxikologie (Vorlesung, wird von Lehrbeauftragten gehalten)
  • Physiologie und Immunologie (Vorlesung)
  • Pharmazeutische Immunologie (Vorlesung)
  • Rekombinante Proteine und Impfstoffe: downstream (Seminar Master)
  • Wahlpflichtfach: Pharmakologie der therapeutischen Antikörper (Seminar)

Qualifikation

Studium der Biochemie und Chemie, Promotion in Pharmakologie (Universität Frankfurt).
Stationen:

  • Wissentschaftliche Mitarbeiterin (Universität Heidelberg)
  • Post-Doc (Sanofi-Aventis/Frankreich)
  • Juniorgruppenleiterin (Inserm/Frankreich)
  • Wissenschaftlerin mit studentischem Team (Boehringer-Ingelheim)
  • Außerdem: Medical Writing (freiberuflich) und klinische Forschung (Quintiles Transnational GmbH)
  • Professorin an der Hochschule Biberach seit 2010.

Forschungsprojekte

  • Assayentwicklung von Validierung von Biomarkern
  • Pharmakologische und pharmakokinetische Testung von Biopharmazeutika
  • Optimierung und Validierung nicht-invasiver Applikationsmethoden für Biopharmazeutika
  • in vivo und in vitro Modelle für die pharmazeutische und Grundlagenforschung

Publikationen

Original articles

20. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Desmercières J, Troquier L, Brouillette J, Tsambou L, Grosjean ME, Caillierez R, Demeyer D, Hamdane M, Schindowski K, Blum D, Buée L. (2011) Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with Tau Pathology? Curr Alzheimer Res. in press

19. SCHINDOWSKI K, von Bohlen und Halbach O, Strelau J, Herrmann O, Ridder DA, Schober A, Schwaninger M, Unsicker K. (2010). Regulation of GDF-15, a novel TGF-beta superfamily member, in a mouse model of cerebral ischemia. Cell Tis Res, 343(2):399-409

18. BELARBI K, SCHINDOWSKI K, BURNOUF S, CAILLIEREZ R, GROSJEAN ME, DEMEYER D, HAMDANE M, SERGEANT N, BLUM D, BUÉE L. (2009). Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer’s disease. Curr Alzheimer Res 6, 152-7 (authors contributed equally).

17. SCHINDOWSKI K, BELARBI K, BRETTEVILLE A, ANDO K, BEGARD S, HAMDANE M, BUÉE L (2008). Neurogenesis and cell-cycle-reactivated neuronal death during pathogenic tau-aggregation. Genes, Brain and Behavior Suppl 1, 92-100.

16. SCHINDOWSKI K, PETERS J, GORRIZ C, SCHRAMM U, WEINANDI T, MAURER K, FRÖLICH L, ECKERT A, MÜLLER WE. (2007). Increased T cell reactivity and elevated levels of CD8+ memory T cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: Implications for immunotherapy. Neuromolecular Med 9, 340-54.

15. KRAUSE S, SCHINDOWSKI K, ZECHEL S, VON BOHLEN UND HALBACH O. (2007). Expression of TrkB and TrkC receptors and their ligands Brain-Derived Neurotrophic Factor and Neuro-trophin 3 in the murine amygdala. Journal of Neuroscience Research 86, 411-21.

14. LEROY K, BRETTEVILLE A, SCHINDOWSKI K, GILISSEN E, AUTHELET E, DE DECKER R, YILMAZ Z, BUÉE L, BRION JP (2007). Severe central and peripheral axonopathy, motor neuron disease and neurofibrillary tangles without neuronal loss in a mutant tau transgenic mice. Am J Pathol 171, 976-92.

13. SCHINDOWSKI K, PETERS J, GORRIZ C, SCHRAMM U, WEINANDI T, LEUTNER S, MAURER K, FRÖLICH L, MÜLLER WE, ECKERT A. (2006). Apoptosis of CD4+ T and Natural Killer cells in Alzheimer’s disease. Pharmacopsychiatry 39, 220-228.

12. SCHINDOWSKI K, BRETTEVILLE A, LEROY K, BÉGARD S, BRION JP, HAMDANE M, BUÉE L. (2006). Alzheimer disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.

11. LEUTNER S, SCHINDOWSKI K, FRÖLICH L, MAURER K, KRATZSCH T, ECKERT A, MÜLLER WE. (2005). Enhanced ROS-generation in lymphocytes from Alzheimer's patients. Pharmacopsy-chiatry. 38, 312-315.

10. HAMDANE M, BRETTEVILLE A, SAMBO AV, SCHINDOWSKI K, BÉGARD S, DELACOURTE A, BERTRAND P, BUÉE L. (2005). p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci 118, 1291-1298.

9. KIPRIANOVA I, SCHINDOWSKI K, VON BOHLEN UND HALBACH O, KRAUSE S, DONO R, SCHWANINGER M, UNSICKER K. (2004). Enlarged infarct volume and loss of BDNF mRNA induc-tion following brain ischemia in mice lacking FGF-2. Exp Neurol 189, 252-260 (authors con-tributed equally).

8. SCHINDOWSKI K, KRATZSCH T, PETERS J, STEINER B, LEUTNER S, TOUCHET N, MAURER K, CZECH C, PRADIER L, FRÖLICH L, MÜLLER WE, ECKERT A. (2003). Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. Neuromolecular Med 4, 161-178.

7. ECKERT A, KEIL U, KRESSMANN S, SCHINDOWSKI K, LEUTNER S, LEUTZ S, MÜLLER WE. (2003). Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 36 Suppl 1, S15-23.

6. SCHINDOWSKI K, FRÖHLICH L, MAURER K, MÜLLER WE, ECKERT A. (2002). Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev 123, 375-390.

5. SCHINDOWSKI K, LEUTNER S, KRESSMANN S, ECKERT A, MÜLLER WE. (2001). Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb761). J Neural Transm 108, 969-978.

4. ECKERT A, SCHINDOWSKI K, LEUTNER S, LUCKHAUS C, TOUCHET N, CZECH C, MÜLLER WE (2001). Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol Dis 8, 331-342.

3. SCHINDOWSKI K, LEUTNER S, MÜLLER WE, ECKERT A (2000). Age-related changes of apoptotic cell death in human lymphocytes. Neurobiol Aging 21, 661-670.

2. LEUTNER S, CZECH C, SCHINDOWSKI K, TOUCHET N, ECKERT A, MÜLLER WE (2000). Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci Lett 292, 87-90.

1. PITZER C, SCHINDOWSKI K, POMER S, WIRTH T, ZÖLLER M (1999). In vivo manipulation of inter-leukin-2 expression by a retroviral tetracycline (tet)-regulated system. Cancer Gene Ther 6, 139-146.

Review articles

2. SCHINDOWSKI K, BELARBI K, BUÉE L. (2008). Neurotrophic factors in Alzheimer’s disease: Role of axonal transport. Genes, Brain and Behavior Suppl 1, 43-56.

1. LEUNER K, PANTEL J, FREY C, SCHINDOWSKI K, SCHULZ K, WEGAT T, MAURER K, ECKERT A, MÜLLER WE (2007). Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. J Neural Transm Suppl. 72, 207-15.

Weitere Publikationen von Frau Prof. Zimmermann